



Takeda Pharmaceuticals International AG
Thurgauerstrasse 130
8152 Glattpark – Opfikon
Switzerland

17 Jan 2025

**Subject: Change of Contact Person(s) for for Plenadren – EMEA/H/C/002185
(EU/1/11/715/001-003 and 006)**

Dear Sir/Madam,

We would like to inform you that the following administrative data of the marketing authorisation application form for the above-mentioned product(s) is being revised:

- ☐ **Contact person at the MAH address to be contacted for the courier delivery of the Commission Decision documents¹** (referred to in section 2.4.1 of the application form for initial marketing authorisation application);
- ☐ **Person/Company authorised for communication on behalf of the applicant during the initial marketing authorisation application in the Union** (referred to in section 2.4.2 of the application form) ²
- ☒ **Person/Company authorised for communication after authorisation** (referred to in section 2.4.3 of the application form) ³
- ☐ **Scientific service of the MAH in the EEA as referred to in Article 98 of Directive 2001/83/EC** (referred to in section 2.4.5 of the application form)
- ☐ **Contact person in the EEA for product defects and recalls, as defined in Article 79 of Directive 2001/83/EC** (referred to in section 2.5.1.1 of the application form)
- ☐ **Contact person for ASMF (Active Substance Master File) holder**

Details of the current and new contact points (select the appropriate option, and duplicate entries if needed):

Current	New
Name: Bhagya Bhavanam Company name: Takeda Pharmaceuticals International AG Address: Takeda Development Centre Europe Ltd 1 Kingdom Street London W2 6BD Country: United Kingdom e-mail: bhagya.bhavanam@takeda.com Please tick this box if person is no longer working for the company. <input checked="" type="checkbox"/>	Name: Nidhikumari Raval Company name: Takeda Pharmaceuticals International AG Ireland Branch Address: Takeda Development Centre Europe Ltd 1 Kingdom Street London W2 6BD Country: United Kingdom Mobile: +44 07735890954 e-mail: nidhikumari.raval@takeda.com

¹ The address given must correspond to the address in SmPC section 7 and the telephone number must be from the same country. It will be used for delivery of all Commission decisions.

² This contact is only used until the Marketing authorisation is granted (i.e. up to when the Commission decision is received)

³ This contact will be used after the Marketing authorisation is granted (i.e. from when the Commission decision is received)

Yours faithfully,

Signed by:

Bhagya BHAVANAM



Signer Name: Bhagya BHAVANAM

Signing Reason: I am the author of this document

Signing Time: 17-Jan-2025 | 21:32:38 JST

7E1ECA9788EE471CB07B2FD9ACABF478

Bhagya Bhavanam

Regulatory Officer

Takeda Development Centre Europe Ltd 1 Kingdom Street London W2 6BD

United Kingdom

e-mail: bhagya.bhavanam@takeda.com

On behalf of Takeda Pharmaceuticals International AG